Contrasting effects of isoproterenol and phosphodiesterase III inhibitor on intracellular calcium transients in cardiac myocytes from failing hearts
- PMID: 7736650
- DOI: 10.1111/j.1440-1681.1994.tb02663.x
Contrasting effects of isoproterenol and phosphodiesterase III inhibitor on intracellular calcium transients in cardiac myocytes from failing hearts
Abstract
1. Effects of a newly developed phosphodiesterase (PDE) III inhibitor, E-1020, on intracellular calcium transients were compared with those of isoproterenol (ISO) in isolated single myocytes from failing hearts secondary to pulmonary hypertension induced by monocrotaline injection. Myocytes were isolated by enzyme digestion using a Langendorff apparatus. Changes in intracellular calcium concentrations ([Ca2+]i) were recorded using a fura-2 fluorescence microscopic technique. Cyclic AMP contents of the hearts were measured by radio-immunoassay. 2. Myocytes from failing hearts showed Ca2+ transients with a low peak (low amplitude) and delayed decline of Ca2+ transients. Both ISO and E-1020 increased peak [Ca2+]i, max + d[Ca2+]i/dt, and max - d[Ca2+]i/dt in a concentration-dependent manner while both agents decreased T80L (time to 80% decline of amplitude from peak light). The concentrations which increased peak [Ca2+]i by 50% were 1.6 x 10(-9) mol/L of ISO and 2 x 10(-6) mol/L of E-1020. These concentrations increased cAMP in the heart to the same levels. Analysis of the effects of both agents on peak [Ca2+]i versus max - d[Ca2+]i/dt showed that ISO is much more effective on peak [Ca2+]i while E-1020 is more effective on max - d[Ca2+]i/dt. 3. These results showed that the effects of ISO and E-1020 on the parameters of intracellular Ca2+ transients of single myocytes from failing hearts are slightly different, and suggest that E-1020 may improve diastolic function as well as systolic function in failing hearts.
Similar articles
-
Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):90-100. doi: 10.1007/BF00167387. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1723153
-
Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.Br J Pharmacol. 1999 May;127(1):65-74. doi: 10.1038/sj.bjp.0702506. Br J Pharmacol. 1999. PMID: 10369457 Free PMC article.
-
EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.Basic Res Cardiol. 1995 Sep-Oct;90(5):365-71. doi: 10.1007/BF00788497. Basic Res Cardiol. 1995. PMID: 8585857
-
Phosphodiesterase inhibition and Ca2+ sensitization.Mol Cell Biochem. 1996 Apr 12-26;157(1-2):245-9. doi: 10.1007/BF00227906. Mol Cell Biochem. 1996. PMID: 8739254 Review.
-
Cyclic AMP phosphodiesterases and Ca2+ current regulation in cardiac cells.Life Sci. 1991;48(25):2365-76. doi: 10.1016/0024-3205(91)90369-m. Life Sci. 1991. PMID: 1646365 Review.
Cited by
-
The Monocrotaline Rat Model of Right Heart Disease Induced by Pulmonary Artery Hypertension.Biomedicines. 2024 Aug 23;12(9):1944. doi: 10.3390/biomedicines12091944. Biomedicines. 2024. PMID: 39335458 Free PMC article. Review.
-
Possible mechanisms underlying the vasodilatation induced by olprinone, a phosphodiesterase III inhibitor, in rabbit coronary artery.Br J Pharmacol. 2000 Mar;129(5):1000-6. doi: 10.1038/sj.bjp.0703125. Br J Pharmacol. 2000. PMID: 10696101 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous